Summary:
Click image to enlargeTo evaluate the efficacy of TAK-279 30 mg orally administered once daily (QD) for 16 weeks, compared to placebo, in subjects with moderate-to-severe plaque psoriasis.
Criteria:- Aged 18 years or older
- Has a diagnosis of chronic plaque psoriasis for ≥6 months prior to the screening visit
- Has plaque psoriasis covering ≥10% of his or her total BSA at screening
- May not have a history of cancer or lymphoproliferative disease within 5 years, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma
- May not have a history of clinically significant drug or alcohol abuse within 12 months
Qualified Participants May Receive:
- Medical Care at no cost
- Up to $2, 175.00 for time and travel